Janssen-Cilag International NV, of Beerse, Belgium, said the European Commission approved Vokanamet, a fixed-dose therapy combining canagliflozin and immediate-release metformin hydrochloride in a single tablet, for the treatment of adults with type 2 diabetes mellitus to improve glycemic control. Canagliflozin as a single agent was approved in Europe in November 2013.